YU77901A - Novi postupak tretmana - Google Patents
Novi postupak tretmanaInfo
- Publication number
- YU77901A YU77901A YU77901A YUP77901A YU77901A YU 77901 A YU77901 A YU 77901A YU 77901 A YU77901 A YU 77901A YU P77901 A YUP77901 A YU P77901A YU 77901 A YU77901 A YU 77901A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- treatment
- mammal
- novel method
- fosiglitazone
- brl49653
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G11—INFORMATION STORAGE
- G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
- G11B20/00—Signal processing not specific to the method of recording or reproducing; Circuits therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
Abstract
Postupak tretmana bolesti ili stanja u vezi sa povećanim brojem neutrofila i/ili preterane aktivacije neutrofila kod sisara, kao što je i čovek, pri čemu se taj postupak sastoji od davanja delotvorne, netoksične i farmaceutski prihvatljive količine agonista PPARγ, kao što je jedinjenje (I), sisaru kome je to potrebno.[A method for treatment of a disease or condition associated with increased numbers of neutrophils and/or neutrophil over-activation in a mammal such as a human, which method comprises administering an effective, non-toxic and pharmaceutically acceptable amount of a PPARγ agonist, such as fosiglitazone (BRL49653) or its maleate salts, or pioglitazone, to a mammal in need thereof.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9908647.2A GB9908647D0 (en) | 1999-04-15 | 1999-04-15 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU77901A true YU77901A (sh) | 2005-07-19 |
Family
ID=10851605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU77901A YU77901A (sh) | 1999-04-15 | 2000-04-17 | Novi postupak tretmana |
Country Status (32)
| Country | Link |
|---|---|
| EP (2) | EP1274407B1 (sh) |
| JP (1) | JP2003516310A (sh) |
| KR (1) | KR20010108506A (sh) |
| CN (1) | CN1413105A (sh) |
| AP (1) | AP2001002291A0 (sh) |
| AT (1) | ATE319437T1 (sh) |
| AU (1) | AU4583000A (sh) |
| BG (1) | BG106104A (sh) |
| BR (1) | BR0009776A (sh) |
| CA (1) | CA2370127A1 (sh) |
| CZ (1) | CZ20013688A3 (sh) |
| DE (1) | DE60026508T2 (sh) |
| DK (1) | DK1274407T3 (sh) |
| DZ (1) | DZ3151A1 (sh) |
| EA (1) | EA200101089A1 (sh) |
| ES (1) | ES2256003T3 (sh) |
| GB (1) | GB9908647D0 (sh) |
| HK (1) | HK1053788A1 (sh) |
| HR (1) | HRP20010746A2 (sh) |
| HU (1) | HUP0300479A2 (sh) |
| ID (1) | ID30339A (sh) |
| IL (1) | IL145875A0 (sh) |
| MA (1) | MA25351A1 (sh) |
| MX (1) | MXPA01010428A (sh) |
| NO (1) | NO20014950L (sh) |
| PL (1) | PL364720A1 (sh) |
| PT (1) | PT1274407E (sh) |
| SK (1) | SK14532001A3 (sh) |
| TR (1) | TR200102977T2 (sh) |
| WO (1) | WO2000062766A2 (sh) |
| YU (1) | YU77901A (sh) |
| ZA (1) | ZA200108446B (sh) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9913782D0 (en) * | 1999-06-14 | 1999-08-11 | Smithkline Beecham Plc | Novel compounds |
| DE50012500D1 (de) * | 2000-11-09 | 2006-05-18 | Phenion Gmbh & Co Kg | Ppar-alpha,beta-aktivatoren zur behandlung von alopecia areata und vitiligo |
| GB0030845D0 (en) * | 2000-12-18 | 2001-01-31 | Smithkline Beecham Plc | Novel treatment |
| GB2373725A (en) * | 2001-03-30 | 2002-10-02 | Novartis Ag | Use of a PPAR gamma agonist in the production of a medicament for the prevention or treatment of diseases associated with IL-10 production |
| EP1465622A1 (en) * | 2001-11-26 | 2004-10-13 | Arachnova Therapeutics Ltd. | Use of ppar activators for the treatment of pulmonary fibrosis |
| DE10204398A1 (de) * | 2002-02-04 | 2003-08-14 | Univ Goettingen Georg August | Neue Verwendung von Liganden der 'Peroxisome Proliferator-Activated receptors'(PPAR) |
| US6992093B2 (en) | 2002-05-02 | 2006-01-31 | Los Angeles Biomedical Research Institute At Harbor Ucla Medical Center | Method of inhibiting lipofibroblast to myofibroblast transdifferentiation |
| US8293479B2 (en) | 2002-05-02 | 2012-10-23 | Los Angeles Biomedical Research Institute At Harbor Ucla Medical Center | Use of parathyroid hormone-related protein(PTHRP) in the diagnosis and treatment of chronic lung disease and other pathologies |
| US20030220300A1 (en) * | 2002-05-14 | 2003-11-27 | Hwang Cheng Shine | Reduction of hair growth |
| ITRM20050389A1 (it) | 2005-07-22 | 2007-01-23 | Giuliani Spa | Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico. |
| KR101333089B1 (ko) | 2006-05-22 | 2013-11-27 | 재단법인 아산사회복지재단 | 로지글리타존을 유효성분으로 함유하는 흡연-유발 만성폐쇄성 폐질환 예방 또는 치료용 약제학적 조성물 |
| GB0913672D0 (en) | 2009-08-05 | 2009-09-16 | Argenta Discovery Ltd | Glitazones |
| US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
| BRPI0917567A2 (pt) * | 2008-08-07 | 2015-11-17 | Pulmagen Therapeutics Inflammation Ltd | tratamento de doença respiratória |
| UA107562C2 (uk) | 2008-12-05 | 2015-01-26 | Спосіб лікування псоріазу | |
| ES2442343T3 (es) | 2008-12-30 | 2014-02-11 | Pulmagen Therapeutics (Inflammation) Limited | Compuestos de sulfonamida para el tratamiento de trastornos respiratorios |
| EP2396082B1 (en) | 2009-02-16 | 2013-07-31 | Nogra Pharma Limited | Methods for treating hair related conditions |
| WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
| WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
| GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| EP2811993B1 (en) | 2012-02-09 | 2019-10-09 | Nogra Pharma Limited | Methods of treating fibrosis |
| NZ631049A (en) | 2012-04-18 | 2017-02-24 | Nogra Pharma Ltd | Methods of treating lactose intolerance |
| WO2016040313A2 (en) * | 2014-09-08 | 2016-03-17 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancer |
| CA3049856C (en) * | 2017-01-13 | 2021-10-26 | Tobishi Pharmaceutical Co., Ltd. | Neutrophil activation regulator |
| US11905232B2 (en) | 2019-02-08 | 2024-02-20 | Nogra Pharma Limited | Process of making 3-(4′-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof |
| JP2020145939A (ja) * | 2019-03-12 | 2020-09-17 | 日本製粉株式会社 | アレルギー性鼻炎抑制用組成物 |
| CN116531374A (zh) * | 2023-04-20 | 2023-08-04 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 吡格列酮及其盐在制备用于治疗系统性红斑狼疮的产品中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9611947D0 (en) * | 1996-06-07 | 1996-08-07 | Glaxo Group Ltd | Medicaments |
| JPH10139665A (ja) * | 1996-09-12 | 1998-05-26 | Sankyo Co Ltd | トログリタゾンを含有するグルタチオン還元酵素活性増強剤 |
| EP1410799B1 (en) * | 1996-12-11 | 2010-03-31 | Dana-Farber Cancer Institute, Inc. | Methods and pharmaceutical compositions for inhibiting tumour cell growth |
| CA2276288A1 (en) * | 1996-12-31 | 1998-07-09 | Laszlo Nagy | Treatment of disease states which result from neoplastic cell proliferation using ppar-gamma activators and compositions useful therefor |
| FR2773075B1 (fr) * | 1997-12-31 | 2000-05-05 | Cird Galderma | Utilisation d'activateurs de ppar-gamma en dermatologie |
| US6028088A (en) * | 1998-10-30 | 2000-02-22 | The University Of Mississippi | Flavonoid derivatives |
-
1999
- 1999-04-15 GB GBGB9908647.2A patent/GB9908647D0/en not_active Ceased
-
2000
- 2000-04-11 DZ DZ003151A patent/DZ3151A1/xx active
- 2000-04-17 IL IL14587500A patent/IL145875A0/xx unknown
- 2000-04-17 EA EA200101089A patent/EA200101089A1/ru unknown
- 2000-04-17 AU AU45830/00A patent/AU4583000A/en not_active Abandoned
- 2000-04-17 WO PCT/GB2000/001499 patent/WO2000062766A2/en not_active Application Discontinuation
- 2000-04-17 CZ CZ20013688A patent/CZ20013688A3/cs unknown
- 2000-04-17 DE DE60026508T patent/DE60026508T2/de not_active Expired - Lifetime
- 2000-04-17 AT AT00927425T patent/ATE319437T1/de not_active IP Right Cessation
- 2000-04-17 HU HU0300479A patent/HUP0300479A2/hu unknown
- 2000-04-17 CA CA002370127A patent/CA2370127A1/en not_active Abandoned
- 2000-04-17 PL PL00364720A patent/PL364720A1/xx not_active Application Discontinuation
- 2000-04-17 BR BR0009776-4A patent/BR0009776A/pt not_active IP Right Cessation
- 2000-04-17 SK SK1453-2001A patent/SK14532001A3/sk unknown
- 2000-04-17 DK DK00927425T patent/DK1274407T3/da active
- 2000-04-17 MX MXPA01010428A patent/MXPA01010428A/es unknown
- 2000-04-17 TR TR2001/02977T patent/TR200102977T2/xx unknown
- 2000-04-17 EP EP00927425A patent/EP1274407B1/en not_active Expired - Lifetime
- 2000-04-17 YU YU77901A patent/YU77901A/sh unknown
- 2000-04-17 CN CN00809014A patent/CN1413105A/zh active Pending
- 2000-04-17 JP JP2000611903A patent/JP2003516310A/ja active Pending
- 2000-04-17 EP EP05076787A patent/EP1593379A3/en not_active Withdrawn
- 2000-04-17 AP APAP/P/2001/002291A patent/AP2001002291A0/en unknown
- 2000-04-17 PT PT00927425T patent/PT1274407E/pt unknown
- 2000-04-17 ID IDW00200102237A patent/ID30339A/id unknown
- 2000-04-17 KR KR1020017013106A patent/KR20010108506A/ko not_active Application Discontinuation
- 2000-04-17 ES ES00927425T patent/ES2256003T3/es not_active Expired - Lifetime
-
2001
- 2001-10-11 NO NO20014950A patent/NO20014950L/no not_active Application Discontinuation
- 2001-10-12 MA MA26355A patent/MA25351A1/fr unknown
- 2001-10-15 ZA ZA200108446A patent/ZA200108446B/xx unknown
- 2001-10-15 HR HR20010746A patent/HRP20010746A2/hr not_active Application Discontinuation
- 2001-11-13 BG BG106104A patent/BG106104A/xx unknown
-
2003
- 2003-06-23 HK HK03104497.7A patent/HK1053788A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU77901A (sh) | Novi postupak tretmana | |
| AP2002002703A0 (en) | Combinations of depeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diadetes mellitus. | |
| MX9805539A (es) | Uso de un agonista del receptor activado proliferador de peroxisomas alfa y del receptor activado proliferador de peroxisomas gamma, para el tratamiento del sindrome x. | |
| TW200505901A (en) | Muscarinic agonists | |
| LU92681I2 (fr) | Nintédanib, ses tautomères et ses sels, en particulier Nintédanib et ses sels pharmaceutiquement acceptables, en particulier Nintédanib Esilate | |
| AP2001002129A0 (en) | 5HT1 receptor agonists and metoclopramide for the treatment of migrane. | |
| EP1244446A4 (en) | Thrombopoietin mimetics | |
| CA2339218A1 (en) | Methods and compositions for increasing insulin sensitivity | |
| MX9603338A (es) | Uso de sensibilizadores a la insulina para tratar enfermedades renales. | |
| MY155219A (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide | |
| WO2002056745A3 (en) | Method of treating parkinson's disease | |
| HK1058515A1 (en) | Use of pamoic acid for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates. | |
| EP1911446A3 (en) | The use of PPAR-gamma agonists for treating diseases characterised by neuron degeneration, neuron injury or impaired plasticity | |
| AP9901720A0 (en) | Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors. | |
| MY125855A (en) | Treatment of diabetes with a thiazolidinedione and sulphonylurea | |
| AP2000001735A0 (en) | Treatment of diabetes with thiazolidinedione insulin secretagogue and alpha glucocidase inhibitor. | |
| TR200202033T2 (tr) | Epilepsi Tedavisi İçin Terkipler ve Yöntemler | |
| AP2000002002A0 (en) | Method of treatment. | |
| PL327472A1 (en) | Nitrogen oxide (no) synthase inhibitor for use in treatment or polphylaxy of type ii diabetes | |
| TR200000957T2 (tr) | Hiperglisemi tedavisinde tiazolidinedion kullanımı | |
| AU4193800A (en) | Use of tagatose to enhance key blood factors | |
| AP1580A (en) | Sustained release compositions comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt or solvate thereof. | |
| HUP0301103A2 (hu) | Cardialis inzulinrezisztenciával kapcsolatos állapotok kezelése és megelőzése | |
| WO2002013825A8 (en) | Novel pharmaceutical use of quinnoline derivatives | |
| NZ503862A (en) | Use of insulin sensitisers (especially thiazolidinediones) for the treatment of hyperglycaemia |